PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
78.38%
Revenue growth of 78.38% while CRON.TO is flat. Bruce Berkowitz would check if a small edge can widen further.
140.18%
Gross profit growth above 1.5x CRON.TO's 13.98%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
12.00%
EBIT growth above 1.5x CRON.TO's 1.35%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
12.00%
Positive operating income growth while CRON.TO is negative. John Neff might view this as a competitive edge in operations.
14.27%
Positive net income growth while CRON.TO is negative. John Neff might see a big relative performance advantage.
13.68%
Positive EPS growth while CRON.TO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
13.68%
Positive diluted EPS growth while CRON.TO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
38.10%
Positive OCF growth while CRON.TO is negative. John Neff would see this as a clear operational advantage vs. the competitor.
-23.74%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-428.58%
Negative 10Y OCF/share CAGR while CRON.TO stands at 33.73%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-428.58%
Negative 5Y OCF/share CAGR while CRON.TO is at 33.73%. Joel Greenblatt would question the firm’s operational model or cost structure.
-428.58%
Negative 3Y OCF/share CAGR while CRON.TO stands at 33.73%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-115.04%
Negative 10Y net income/share CAGR while CRON.TO is at 48.41%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-115.04%
Negative 5Y net income/share CAGR while CRON.TO is 48.41%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-115.04%
Negative 3Y CAGR while CRON.TO is 48.41%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
123.15%
10Y equity/share CAGR above 1.5x CRON.TO's 5.16%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
123.15%
5Y equity/share CAGR above 1.5x CRON.TO's 5.16%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
123.15%
3Y equity/share CAGR above 1.5x CRON.TO's 5.16%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
50.45%
AR growth of 50.45% while CRON.TO is zero. Bruce Berkowitz wonders if the firm’s additional AR is warranted by strong revenue or potential risk.
11.96%
Inventory growth of 11.96% while CRON.TO is zero. Bruce Berkowitz wonders if we anticipate a new wave of demand or risk being stuck with extra product.
-4.73%
Negative asset growth while CRON.TO invests at 0.73%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-9.17%
We have a declining book value while CRON.TO shows 2.43%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.27%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.